2018 Nephrotic Syndrome Pipeline Review, H1 - ResearchAndMarkets.com

DUBLIN--()--The "Nephrotic Syndrome - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Nephrotic Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 1 and 3 respectively.

Companies Mentioned

  • Asahi Kasei Pharma Corp
  • Aurinia Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Orbis Biosciences Inc
  • Pfizer Inc

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Nephrotic Syndrome - Overview
  4. Nephrotic Syndrome - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Nephrotic Syndrome - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Nephrotic Syndrome - Companies Involved in Therapeutics Development
  14. Asahi Kasei Pharma Corp
  15. Aurinia Pharmaceuticals Inc
  16. Bristol-Myers Squibb Co
  17. Orbis Biosciences Inc
  18. Pfizer Inc
  19. Nephrotic Syndrome - Drug Profiles
  20. abatacept - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. mizoribine - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. PF-06730512 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. prednisone - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. voclosporin - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. Nephrotic Syndrome - Dormant Projects
  41. Appendix
  42. Methodology
  43. Coverage
  44. Secondary Research
  45. Primary Research
  46. Expert Panel Validation

For more information about this report visit https://www.researchandmarkets.com/research/mnbcn6/2018_nephrotic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs